Does Fosamax Cause Osteonecrosis of the Jaw?

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Information to Occupational Exposure

The legacy context of general health and science information has long served as a foundational resource for public understanding of medical conditions and therapeutic options. Within this broad domain, discussions of bone health and the management of osteoporosis have been prominent, often emphasizing the benefits of pharmacological interventions such as bisphosphonates. This heritage provides a baseline for recognizing how patients and clinicians navigate treatment decisions based on established medical knowledge. As we pivot from this general health framework toward a more specific occupational exposure concern, it becomes necessary to consider how the same therapeutic agents, when encountered in non-clinical settings, may present distinct risk profiles. The transition from patient-oriented health information to an occupational lens requires acknowledging that exposure to substances like Fosamax is not limited to prescribed use. In manufacturing, handling, or disposal environments, workers may come into contact with this compound under conditions that differ markedly from controlled medical administration. This shift in perspective invites a focused examination of how occupational exposure pathways could influence health outcomes, moving beyond the patient-clinic dynamic to consider workplace safety and industrial hygiene. The bridge concept thus reframes the discussion from general health literacy to a targeted inquiry into the potential risks associated with Fosamax exposure in occupational contexts.

Fosamax and Osteonecrosis of the Jaw: Medical Evidence

Fosamax (alendronate sodium) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its primary mechanism involves increasing bone mass and reducing fracture incidence, including hip and spine fractures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a serious adverse effect associated with bisphosphonates, including Fosamax, is osteonecrosis of the jaw (ONJ). Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region, often associated with tooth extraction, local infection, or delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Clinical presentation typically involves pain, swelling, infection, and exposed bone that fails to heal within eight weeks. Diagnosis relies on clinical examination and imaging, with exclusion of metastatic disease. The condition can occur spontaneously but is more commonly linked to dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Mechanisms Linking Fosamax to Jaw Necrosis

The mechanistic pathways linking Fosamax to ONJ involve bisphosphonate-induced suppression of bone turnover. Bisphosphonates inhibit osteoclast activity, reducing bone resorption and remodeling. In the jawbone, which has high turnover rates due to constant mechanical stress and dental infections, this suppression can lead to microdamage accumulation, impaired healing, and eventual necrosis. Multiscale characterization of jawbone tissue has provided insights into its unique responses to bisphosphonate-related complications, including ONJ (https://pubmed.ncbi.nlm.nih.gov/40345077). Additionally, bisphosphonates may impair angiogenesis and immune function, further compromising tissue repair.

Risk Factors and Clinical Considerations

Risk factors for developing ONJ while on Fosamax include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, or ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with longer duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The timeline between Fosamax exposure and documented harm varies. The time to onset of symptoms after starting the drug can range from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients experience relief of symptoms after discontinuation, but a subset may have recurrence if rechallenged with the same or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups, suggesting that ONJ is a rare event in the general osteoporosis population (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Adequacy of Warnings and Causation

Adequacy of warnings regarding Fosamax and ONJ is addressed in the prescribing information. The label includes a specific section on osteonecrosis of the jaw, detailing risk factors, association with dental procedures, and recommendations for management (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the label also notes that in clinical trials, the incidence of ONJ was low and similar to placebo, which may lead to underappreciation of risk in routine practice. For affected patients, causation considerations include the presence of other risk factors, duration of therapy, and temporal relationship between drug initiation and ONJ onset. The label advises discontinuation if severe symptoms develop and suggests that stopping bisphosphonate treatment before invasive dental procedures may reduce risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). In summary, Fosamax is associated with osteonecrosis of the jaw, a serious but rare adverse event. The evidence supports a causal link through bisphosphonate-mediated suppression of bone turnover, particularly in the jawbone. Risk is heightened by dental procedures, longer exposure, and concomitant medications. Warnings in the prescribing information are present but may not fully convey the risk to all patients. Clinicians should assess individual risk factors and consider dental evaluation before initiating therapy.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is osteonecrosis of the jaw (ONJ)?

Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region, often associated with tooth extraction, local infection, or delayed healing. Clinical presentation typically involves pain, swelling, infection, and exposed bone that fails to heal within eight weeks. Diagnosis relies on clinical examination and imaging, with exclusion of metastatic disease. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56)

How does Fosamax cause osteonecrosis of the jaw?

Fosamax (alendronate) is a bisphosphonate that inhibits osteoclast activity, reducing bone turnover. In the jawbone, which has high turnover rates, this suppression can lead to microdamage accumulation, impaired healing, and eventual necrosis. Bisphosphonates may also impair angiogenesis and immune function, further compromising tissue repair. (https://pubmed.ncbi.nlm.nih.gov/40345077)

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, or ill-fitting dentures. The risk may increase with longer duration of bisphosphonate exposure. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1)

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Check Whether Your Situation Qualifies

Free and confidential. No obligation — an initial records screening only.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.